In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies<a href="https://solaci.org/en/2020/04/22/are-non-culprit-lesions-really-innocent/" title="Read more" >...</a>
Since November 2015, when the LEADERS FREE was published in NEJM, polymer-free drug coated stents had undoubtedly been the best treatment for patients at high risk of bleeding. The benefit was owed to the safety and efficacy of the polymer-free biolimus coated stent (also called umirolimus) vs. bare metal stents in the context of just<a href="https://solaci.org/en/2020/02/27/onyx-one-more-options-for-patients-at-high-risk-for-bleeding/" title="Read more" >...</a>
01- Soon after the EXCEL “Scandal” the NOBLE 5-year Outcomes Come Out: Mere Coincidence? There is no such thing as coincidence, at least not for the evidence-based medical science. This is what the NOBLE 5-year outcomes, soon to be published in the Lancet, seem to say, in line with the BBC exposé of the EXCEL<a href="https://solaci.org/en/2020/02/05/the-most-read-scientific-articles-of-january-in-solaci-org/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Advanced peripheral vascular disease is frequently associated with cardiovascular events and amputation. It has been proven that mono-antiplatelet therapy (MAPT) offers some benefit (with either aspirin or clopidogrel), but there are scarce data on the role of dual antiplatelet therapy (DAPT) in these patients. Researchers analyzed 404 patients who received MAPT for<a href="https://solaci.org/en/2020/01/07/we-should-indicate-more-than-6-months-of-dapt-in-lower-limb-disease/" title="Read more" >...</a>
1- ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes” In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This document, simultaneously published in Euro Heart J, updates the 2013 guidelines on stable ischemic heart disease and<a href="https://solaci.org/en/2019/10/21/the-most-read-scientific-articles-in-september-at-solaci-org/" title="Read more" >...</a>
Courtesy of SBHCI. This study tested the safety of dual antiplatelet therapy (DAPT) after only three months of bioresorbable polymer sirolimus DES implantation (Ultimaster). Secondary end point was following with P2Y12 inhibitor monotherapy after the first 3 months compared with aspirin. It included 1695 patients treated with sirolimus eluting Ultimaster receiving 3-month DAPT. After the<a href="https://solaci.org/en/2019/09/30/tct-2019-model-u-ses-more-devices-for-high-risk-of-bleeding-and-short-dapt/" title="Read more" >...</a>
Courtesy of SBHCI. This study showed that using the everolimus eluting stent with bioabsorbable polymer Synergy followed by 4 months of dual antiplatelet therapy (DAPT) to treat left main stenosis (LMS) was safe and effective, compared against using the everolimus eluting stent with permanent polymer Xience followed by the conventional 12 months DAPT. This study<a href="https://solaci.org/en/2019/09/30/tct-2019-ideal-lm-bioabsorbable-polymer-des-vs-permanent-polymer-des-for-left-main-stenosis/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been proven long ago, and both prasugrel and ticagrelor have offered best results than clopidogrel. However, nowadays, it is unclear which of them is superior in the long term, taking into account the fact that one starts to<a href="https://solaci.org/en/2019/09/05/esc-2019-isar-react-5-which-is-better-in-acs-prasugrel-or-ticagrelor/" title="Read more" >...</a>
1-Though Systolic BP Seems More Important, Diastolic BP Should Not Be Disregarded Systolic hypertension is more often associated to cardiovascular events. However, diastolic blood pressure should not be disregarded, since it can also predict even worse outcomes. Read more HERE 2-After Much Toing and Froing, Gastrointestinal Protection Is Back to the Forefront Several clinical guidelines<a href="https://solaci.org/en/2019/08/30/the-most-read-articles-of-july-in-solaci-website/" title="Read more" >...</a>
Several clinical guidelines differ in their recommendation regarding the prescription of proton pump inhibitors to patients being treated with dual antiplatelet therapy after infarction. In 2015, the European Society of Cardiology (ESC) recommended their use in patients with high bleeding risk; however, in the 2017 update that recommendation became general after the assumption that, for<a href="https://solaci.org/en/2019/07/14/after-much-toing-and-froing-gastrointestinal-protection-is-back-to-the-forefront/" title="Read more" >...</a>